NPCE
NeuroPace, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
25.10
P/S
4.92
EV/EBITDA
-39.19
DCF Value
$-33.88
FCF Yield
-2.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.2%
Operating Margin
-16.3%
Net Margin
-21.5%
ROE
-105.7%
ROA
-20.3%
ROIC
-18.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $26.6M | $-2.7M | $-0.08 |
| FY 2025 | $100.0M | $-21.5M | $-0.66 |
| Q3 2025 | $27.4M | $-3.5M | $-0.11 |
| Q2 2025 | $23.5M | $-8.7M | $-0.26 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.88
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.